Key result
The CaMKII inhibitor KN-93 completely prevented action potential duration alternans and abolished ventricular fibrillation (0% vs 60%, P<0.05) during rapid pacing in hypertrophied rat hearts.
Why the study?
Does CaMKII inhibition with KN-93 reduce susceptibility to APD-ALT and ventricular fibrillation in spontaneously hypertensive rats?
Does CaMKII inhibition with KN-93 reduce susceptibility to APD-ALT and ventricular fibrillation in spontaneously hypertensive rats?
Absolute Event Rate: 0% vs 60%
p-value: p=<0.05
CaMKII inhibition prevents increased susceptibility to action potential duration alternans and ventricular fibrillation in hypertrophied hearts of spontaneously hypertensive rats.
No takes yet. Share an insight, caveat, or question.
May support CaMKII inhibition against hypertrophy-related arrhythmias; leaves open translation to human therapy.
Mitsuyama et al. (2014) studied Cardiac hypertrophy (n=20). KN-93 (CaMKII inhibitor) vs. KN-92 (inactive analog) or untreated SHR was evaluated on Ventricular fibrillation (VF) induced by rapid pacing (p=<0.05). The CaMKII inhibitor KN-93 completely prevented action potential duration alternans and abolished ventricular fibrillation (0% vs 60%, P<0.05) during rapid pacing in hypertrophied rat hearts.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: